Who is sponsoring NCT01667263?

NCT01667263 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT01667263?

Interventions in NCT01667263: All-trans retinoic acid, Danazol.

What condition does NCT01667263 study?

NCT01667263 studies Autoimmune Thrombocytopenia.

Is NCT01667263 still recruiting?

NCT01667263 is currently completed. Last updated 7 September 2017.

Last reviewed 2017-09-07 · How we verify

NCT01667263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Completed Phase 2 Last updated 7 September 2017

What this trial tests

Phase 2 trial testing All-trans retinoic acid in Autoimmune Thrombocytopenia in 130 participants. Completed in 1 February 2017.

Timeline

1 June 2012

Primary endpoint
1 July 2016

1 February 2017

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	130
Start date	1 June 2012
Primary completion	1 July 2016
Estimated completion	1 February 2017
Sites	5 locations across China

Drugs / interventions tested

All-trans retinoic acid
Danazol (DANAZOL) — full drug profile →

Conditions studied

Autoimmune Thrombocytopenia — all drugs for Autoimmune Thrombocytopenia →

Sponsor

Peking University People's Hospital

Who can join

18 and older, any sex, with Autoimmune Thrombocytopenia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

The path toward using microbial metabolites as therapies.
Descamps HC, Herrmann B, Wiredu D, Thaiss CA. · · 2019 · cited 77× · PMID 31201140 · DOI 10.1016/j.ebiom.2019.05.063
Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers.
Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, et al · · 2023 · cited 52× · PMID 37645246 · DOI 10.3389/fcell.2023.1254612
Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Feng FE, Feng R, Wang M, Zhang JM, et al · · 2017 · cited 40× · PMID 28917657 · DOI 10.1016/s2352-3026(17)30170-9
Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Lv Y, Shi H, Liu H, Zhou L. · · 2022 · cited 23× · PMID 36003388 · DOI 10.3389/fimmu.2022.953716

Verify or expand the search:

Other trials of All-trans retinoic acid

Trials testing the same drug.

NCT07187505 — Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia · NA · active not recruiting
NCT06646666 — ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and AS · Phase 2 · not yet recruiting
NCT05345002 — All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma · Phase 2 · recruiting
NCT04700176 — A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma · Phase 2 · terminated
NCT04793919 — Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia · Phase 2 · recruiting

Other recruiting trials for Autoimmune Thrombocytopenia

Currently open trials in the same condition.

NCT06826430 — Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocy · Phase 1 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01667263 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 7 September 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01667263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing